Gupta K, Perchik JD, Fang AM, Porter KK, Rais-Bahrami S. Augmenting prostate magnetic resonance imaging reporting to incorporate diagnostic recommendations based upon clinical risk calculators. World J Radiol 2022; 14(8): 249-255 [PMID: 36160831 DOI: 10.4329/wjr.v14.i8.249]
Corresponding Author of This Article
Soroush Rais-Bahrami, MD, Associate Professor, Departments of Urology and Radiology, University of Alabama at Birmingham, Faculty Office Tower 1107 510 20th Street South, Birmingham, AL 35233, United States. soroushraisbahrami@gmail.com
Research Domain of This Article
Radiology, Nuclear Medicine & Medical Imaging
Article-Type of This Article
Opinion Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Radiol. Aug 28, 2022; 14(8): 249-255 Published online Aug 28, 2022. doi: 10.4329/wjr.v14.i8.249
Augmenting prostate magnetic resonance imaging reporting to incorporate diagnostic recommendations based upon clinical risk calculators
Karisma Gupta, Jordan D Perchik, Andrew M Fang, Kristin K Porter, Soroush Rais-Bahrami
Karisma Gupta, Department of Radiology, University of Washington, Seattle, WA 98195, United States
Jordan D Perchik, Kristin K Porter, Soroush Rais-Bahrami, Department of Radiology, University of Alabama at Birmingham, Birmingham, AL 35233, United States
Andrew M Fang, Soroush Rais-Bahrami, Department of Urology, University of Alabama at Birmingham, Birmingham, AL 35233, United States
Soroush Rais-Bahrami, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, United States
Author contributions: Porter KK and Rais-Bahrami S contributed equally to this work; Porter KK and Rais-Bahrami S designed the study; Gupta K, Perchik JD, Fang AM, Porter KK, and Rais-Bahrami S contributed to authoring the manuscript and critically reviewing and revising the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Rais-Bahrami S serves as a consultant to Philips/InVivo Corp, Genomic Health Inc, Blue Earth Diagnostics, Bayer Healthcare, UroViu Corp, and Intuitive Surgical.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Soroush Rais-Bahrami, MD, Associate Professor, Departments of Urology and Radiology, University of Alabama at Birmingham, Faculty Office Tower 1107 510 20th Street South, Birmingham, AL 35233, United States. soroushraisbahrami@gmail.com
Received: March 22, 2022 Peer-review started: March 22, 2022 First decision: June 16, 2022 Revised: June 27, 2022 Accepted: July 25, 2022 Article in press: July 25, 2022 Published online: August 28, 2022 Processing time: 156 Days and 14.8 Hours
Abstract
Risk calculators have offered a viable tool for clinicians to stratify patients at risk of prostate cancer (PCa) and to mitigate the low sensitivity and specificity of screening prostate specific antigen (PSA). While initially based on clinical and demographic data, incorporation of multiparametric magnetic resonance imaging (MRI) and the validated prostate imaging reporting and data system suspicion scoring system has standardized and improved risk stratification beyond the use of PSA and patient parameters alone. Biopsy-naïve patients with lower risk profiles for harboring clinically significant PCa are often subjected to uncomfortable, invasive, and potentially unnecessary prostate biopsy procedures. Incorporating risk calculator data into prostate MRI reports can broaden the role of radiologists, improve communication with clinicians primarily managing these patients, and help guide clinical care in directing the screening, detection, and risk stratification of PCa.
Core Tip: Incorporating risk calculator data into prostate magnetic resonance imaging reports can broaden the role of radiologists, improve communication with clinicians primarily managing these patients, and help guide clinical care in directing the screening, detection, and risk stratification of prostate cancer.
